Meirluc, Agree. I did an AI search and here's what I found as clinical data support poly-ICLC's safety and potential efficacy in GBM, other than the UCLA phase 2 trial:
Phase II trials demonstrated improved survival when combined with radiotherapy and temozolomide in newly diagnosed GBM, with median overall survival of 18.3 months vs. 14.6 months in controls. 2010 https://pmc.ncbi.nlm.nih.gov/articles/PMC3018929/
Pediatric trials reported stable disease in low-grade glioma patients and manageable toxicity (e.g., transient fever, mild injection-site reactions). 2015 https://pmc.ncbi.nlm.nih.gov/articles/PMC4356196/
Preclinical and clinical evidence suggests synergy with vaccines and immune checkpoint inhibitors by enhancing dendritic cell maturation and T-cell activation. 2021 https://pmc.ncbi.nlm.nih.gov/articles/PMC8229304/
In the United States, oncologists may prescribe FDA-approved drugs for off-label uses under their medical discretion, provided the decision is evidence-based and prioritizes patient safety.
Market Data 
Markets 
AI
